Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab

PHASE3CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

December 31, 2004

Study Completion Date

November 30, 2006

Conditions
Hemoglobinuria, Paroxysmal
Interventions
DRUG

eculizumab

Trial Locations (48)

8

St. James Hospital, Haematology Dept., Cancer Clinical Trial Office, Dublin

1200

Ucl St. Luc, Hematology Department, Brussels

2065

Royal North Shore Hospital, Haematology Department, Saint Leonard

3050

Royal Melbourne Hospital, Dept. of Clinical Haematology & Medical Oncology, Parkville

4102

Princess Alexandra Hospital, Oncology Haematology Radiation Department, Woolloongabba

5011

The Queen Elizabeth Hospital, Haematology/Oncology Department, Woodville South

6000

The Royal Perth Hospital, Dept. of Haematology/Level 2, Perth

10016

NYU Clinical Cancer Center, New York

10017

Memorial Sloan Kettering Cancer Center, New York

14263

Roswell Park Cancer Institute, Buffalo

19104

Presbyterian Medical Center, PENN Comprehensive Hemophilia & Thrombosis Program, Philadelphia

20892

National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda

21205

Johns Hopkins University Medical Center, Baltimore

27710

Duke University Medical Center, Division Cell Therapy, Heme Malignancies Program, Durham

28046

Hospital De La Paz, Servicio de Hematologia, Madrid

33331

Cleveland Clinic Florida, Dept. of Clinical Research, Weston

44195

The Cleveland Clinic Foundation, Cleveland

46202

Indiana University Cancer Pavilion, Indianapolis

50139

Azienda Ospedaliera Universitaria Careggi, Dipartimento di area critica medico-chirurgica, Florence

55905

Mayo Clinic, Division of Hematology, Rochester

63110

Washington University Medical Center, Department of Internal Medicine/Division of Hematology, St Louis

84132

University of Utah, Hematology-BMT Department, Salt Lake City

90033

Norris Comprehensive Cancer Center, Los Angeles

94305

Stanford University Medical Center, Division of Hematology, Stanford

97239

OHSU Center for Hematologic Malignancies, Portland

06102

Hartford Hospital, Cancer Clinical Research Office, Hartford

02114

Massachusetts General Hospital, Boston

08043

Cooper University Hospital, Cooper Cancer Institute, Voorhees Township

T6G 2B7

University of Alberta, Cross Cancer Institute, Edmonton

N6A 4L6

London Regional Cancer Centre, Clinical Research Unit Room C3080, London

10 75475

Hopital Saint-Louis, Centre d'investigation Clinique, Paris

D-45147

Universitatsklinikum Essen, Zentrum fur Innere Medizin, Essen

D-30625

Medizinische Hochschule Hannover, Abt. Hamatologie/Onkologie, Zentrum fur Innere Medizin, Hanover

D-66421

Universitatskliniken des Saarlandes, Innere Medizin 1, Homburg/Saar

D-89081

Institut fur Klinische Transfusionmedizin und Immungenetik, Abtlg. Transfusionmedizin des Univer. Ulm, Ulm

I-16132

Ospedale San Martino, Dept. of Hematology, Genova

35-20122

Ospedale Maggiore di Milano, Divisione di Ematologia, Milan

5-80131

Universita degli Studi di Napoli, Divisione di Ematologia, Azienda Universitar Policlinico, Napoli

37-36100

Ospedale San Bortolo, Divisione di Ematologia, Vicenza

6525 GA

UMC St. Radboud, Department of Hematology, Nijmegen

08036

Hospital Clinic i Provincial, Servicio de Hematologia, Barcelona

08916

Hospital Universitario Germans Trias I Pujol, Servicio de Hematologia, Barcelona

118-83

Stockholm South Hospital, Division of Hematology, Stockholm

SE-751

University Hospital, Dept. of Haematology, Uppsala

CH-4031

Kantonsspital Basel, Abteilung fuer Haematologie, Basel

TR1 3LJ

Royal Cornwall Hospital, Truro

LS1 3EX

Leeds General Infirmary, D Floor Brotherton Wing, Leeds

17 OQT

St. Georges Hospital, Department of Haematology, London

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY